ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Profitability
This table compares ClearPoint Neuro and Bluejay Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ClearPoint Neuro | -66.15% | -94.44% | -51.58% |
| Bluejay Diagnostics | N/A | -362.07% | -299.10% |
Earnings and Valuation
This table compares ClearPoint Neuro and Bluejay Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ClearPoint Neuro | $31.39 million | 9.27 | -$18.91 million | ($0.81) | -12.64 |
| Bluejay Diagnostics | $250,000.00 | 7.99 | -$7.72 million | ($125.15) | -0.01 |
Bluejay Diagnostics has lower revenue, but higher earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
ClearPoint Neuro has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.
Institutional & Insider Ownership
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 7.0% of ClearPoint Neuro shares are owned by insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for ClearPoint Neuro and Bluejay Diagnostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ClearPoint Neuro | 0 | 0 | 3 | 0 | 3.00 |
| Bluejay Diagnostics | 0 | 0 | 0 | 0 | 0.00 |
ClearPoint Neuro currently has a consensus price target of $19.6667, indicating a potential upside of 92.06%. Given ClearPoint Neuro’s stronger consensus rating and higher probable upside, research analysts plainly believe ClearPoint Neuro is more favorable than Bluejay Diagnostics.
Summary
ClearPoint Neuro beats Bluejay Diagnostics on 11 of the 14 factors compared between the two stocks.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
